Table 1.
Clinical and pathological features
| Variables | No. of cases | Percentage (%) |
|---|---|---|
| Age | ||
| ≤49 years | 37 | 26.6% |
| >49 years | 102 | 73.4% |
| Tumor size (cm) | ||
| ≤2 | 38 | 27.3% |
| 2< size ≤5 | 89 | 64% |
| >5 | 12 | 8.6% |
| Lymph node status | ||
| N0 | 73 | 52.5% |
| N1 | 36 | 25.9% |
| N2 | 19 | 13.7% |
| N3 | 11 | 7.9% |
| Pathological grade | ||
| I | 10 | 7.2% |
| II | 94 | 67.6% |
| III | 35 | 25.2% |
| Clinical stage | ||
| 0 | 1 | 0.7% |
| I | 23 | 16.5% |
| II | 79 | 56.8% |
| III | 36 | 25.9% |
| ER | ||
| Positive | 77 | 55.4% |
| Negative | 62 | 44.6% |
| PR | ||
| Positive | 34 | 24.5% |
| Negative | 105 | 75.5% |
| HER2 | ||
| Positive | 43 | 30.9% |
| Negative | 96 | 69.1% |
| Ki-67 | ||
| >14% | 41 | 29.5% |
| ≤14% | 98 | 70.5% |
| AR | ||
| Positive | 94 | 67.6% |
| Negative | 45 | 32.4% |
| EGFR | ||
| Positive | 21 | 15.1% |
| Negative | 118 | 84.9% |
| 14-3-3 sigma | ||
| Positive | 63 | 45.3% |
| Negative | 76 | 54.7% |
| Subtype | ||
| Luminal A | 51 | 36.7% |
| Luminal B | ||
| Her-2 (-) | 13 | 9.4% |
| Her-2 (+) | 15 | 10.8% |
| Erb-B2 overexpression | 27 | 19.4% |
| TNBC (Triple negative) | 33 | 23.7% |